INNOVENT BIO (01801) has announced that all preconditions for the strategic collaboration agreement with Eli Lilly, initially disclosed on February 8, 2026, to advance new drug development in oncology and immunology, have now been satisfied. The company has received early termination of the waiting period under the Hart-Scott-Rodino Act. Consequently, the strategic collaboration agreement became effective on March 24, 2026, Hong Kong time. The company noted that some media reports have mistakenly interpreted the agreement's effectiveness as an acquisition of the company. INNOVENT BIO hereby clarifies that it has not, and has no intention to, engage in such a transaction. Shareholders and potential investors are advised not to rely on market rumors concerning the group. Any information about the group should be sourced solely from the company's official announcements.